Companies / QURE uniQure N.V. (QURE)
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Ticker QURE Exchange Nasdaq Sector Healthcare Industry Biotechnology Market cap $1.52B 52-week range $8.73 - $51.72 Valuation Share price $21.70 (close of Nov 6, 2026) P/E (TTM) -6.15x Price to book 5.16x Price to free cash flow -7.88x Enterprise value $1.48B Book value per share $4.21 Price performance Period Change 1 day +3.28% 5 days -12.61% 1 month -5.90% 3 months -52.16% 6 months -4.91% Year to date -9.32% 1 year -21.12% 3 years +255.16% 5 years -38.40% 10 years +206.93% All time +48.53%
Short interest As of Oct 15, 2026 Short % of float 12.75% Shares short 8.73M Days to cover 3.84 Change since prior report +0.12% Source FINRA consolidated short interest Profitability and growth Return on equity -100.04% Return on invested capital -70.66% Return on assets -24.12% Return on capital employed -24.32% Gross margin 89.53% Net margin -1,236.00% EBITDA margin -1,059.70% Revenue growth -40.64% Cash flow and balance sheet Free cash flow yield (TTM) -12.69% Current ratio 11.52x Net debt to EBITDA 0.23x Latest reported year Period end Dec 31, 2025 Fiscal year 2025 Revenue $16.10M Cost of revenue $1.69M Gross profit $14.41M EBITDA -$170.59M Net income -$198.97M Earnings per share $-3.46 Research and development $140.67M Interest expense $61.99M Shares outstanding 57.50M Income statement by year Period end Revenue Gross profit Net income EPS 2025-12-31 $16.10M $14.41M -$198.97M -$3.46 2024-12-31 $27.12M $25.85M -$239.56M -$4.92 2023-12-31 $15.84M $15.78M -$308.48M -$6.47 2022-12-31 $106.48M $105.23M -$126.79M -$2.71 2021-12-31 $524.00M $499.03M $329.59M $7.17 2020-12-31 $37.51M $34.62M -$125.02M -$2.81 2019-12-31 $7.28M $5.63M -$124.20M -$3.11 2018-12-31 $11.28M $10.08M -$83.30M -$2.34 2017-12-31 $13.11M $12.29M -$79.26M -$2.94 2016-12-31 $25.10M $23.75M -$73.37M -$2.93
Margins and returns by year Period end Gross margin Net margin Return on equity Return on capital 2025-12-31 89.53% -1,236.00% -100.04% -70.66% 2024-12-31 95.33% -883.35% - - 2023-12-31 99.59% -1,947.09% -148.54% -81.74% 2022-12-31 98.82% -119.07% -26.64% -22.89% 2021-12-31 95.23% 62.90% 55.32% 42.02% 2020-12-31 92.27% -333.27% -51.26% -34.56% 2019-12-31 77.28% -1,705.82% -38.45% -30.58% 2018-12-31 89.35% -738.25% -46.38% -41.02% 2017-12-31 93.77% -604.72% -88.70% -64.59% 2016-12-31 94.63% -292.35% -115.31% -85.79%
Cash and debt by year Period end Cash Debt 2025-12-31 $80.24M $49.70M 2024-12-31 $158.93M $51.32M 2023-12-31 $241.36M $101.75M 2022-12-31 $228.01M $102.79M 2021-12-31 $556.26M $100.96M 2020-12-31 $244.93M $35.62M 2019-12-31 $377.79M $36.06M 2018-12-31 $234.90M $35.47M 2017-12-31 $159.37M $19.74M 2016-12-31 $132.50M $19.63M
Free cash flow by year Period end Free cash flow Stock-based compensation 2025-12-31 -$178.40M $17.68M 2024-12-31 -$186.10M $22.26M 2023-12-31 -$153.08M $35.09M 2022-12-31 -$162.75M $34.20M 2021-12-31 $270.52M $25.64M 2020-12-31 -$142.10M $21.83M 2019-12-31 -$104.33M $17.53M 2018-12-31 -$78.42M $10.71M 2017-12-31 -$68.73M $10.28M 2016-12-31 -$87.48M $6.21M
Investor relations Past earnings dates Reported Fiscal period EPS estimate 2026-11-04 Sep 2026 -$0.84 2026-07-29 Jun 2026 -$0.81 2026-05-05 Mar 2026 -$0.88 2026-03-02 Dec 2025 -$0.93 2025-11-10 Sep 2025 -$0.85 2025-07-29 Jun 2025 -$0.89 2025-05-09 Mar 2025 -$1.07 2025-02-27 Dec 2024 -$0.44
Filings and sources Company website uniqure.com SEC filings 10-K, 10-Q and 8-K on EDGAR Earnings calendar All upcoming reports Similar companies Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades